Fig. 5: oHSV30 enhanced migration, lytic activity and persistence of CAR-T cells. | Cell Death & Disease

Fig. 5: oHSV30 enhanced migration, lytic activity and persistence of CAR-T cells.

From: Arming oncolytic herpes simplex virus with CXCL-11, IL-12 and a single-chain antibody against PD-1 to enhance CAR-T cell therapy in pancreatic ductal adenocarcinoma

Fig. 5: oHSV30 enhanced migration, lytic activity and persistence of CAR-T cells.The alternative text for this image may have been generated using AI.

A Scheme showing the construction of oncolytic herpes simplex viruses oHSV30. B Panc2-mCD19-HVEM cells were cultured in plates and infected with oHSV11, oHSV12, oHSV-α PD-1, or oHSV30 at an MOI of 1. CAR-T cells were co-cultured with the infected Panc2-mCD19-HVEM cells. The number of tumour cells was analyzed by flow cytometry (n = 3 experiments). C–F CAR-T cells (2 × 105) were plated in the upper chambers and the lower chambers contained Panc2-mCD19-HVEM (5 × 104) infected with oHSV11, oHSV12, oHSV-PD-1, oHSV30, or saline control. The lysis of tumour cells, the migration of CAR-T cells towards the lower chambers, IFN-γ production in CAR-T cells and the proliferation of CAR-T cells were analyzed by flow cytometry (n = 3 experiments). Data represent the mean ± SD. Statistical significance is calculated by one-way ANOVA with Tukey’s significant difference multiple comparisons (B–F). ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Back to article page